Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Aptus Pharma Limited Major Shareholding Notification 2026

May 14, 2026

60448_rns_2026-05-14_832c2515-26dd-41c2-8dd6-e935454e2d52.pdf

Major Shareholding Notification

Open in viewer

Opens in your device viewer

KUNJAL PIYUSHBHAI UNADKAT

Address: Block No. B – 801, 8th Floor, Savan Symphony Tower, Raiya Road, Rajkot – 360005

To,

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001

Dear Sir,

Sub.: Disclosure under Regulation 29 of SEBI Regulation, 2011 (Substantial Acquisition of Shares and Takeover)

Ref.: Name- APTUS PHARMA LIMITED (INE15XJ01010) – CODE - APPL

With reference to the subject matter, enclosed herewith please find the details of Shares Purchase of Aptus Pharma Limited in term of Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeover) Regulation, 2011 on 11.05.2026

Kindly take the same on your records and acknowledge the receipt.

Kunjal P. Unadkat
Kunjal Piyushbhai Unadkat

Date: 13.05.2026
Place: Rajkot


Disclosures under Regulation 29(1) of Securities and Exchange Board of India(Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Date: 13.05.2026

To,

BSE Limited
Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001

Aptus Pharma Limited
Attn: The Compliance Officer

Sub: Disclosure under Regulation 29(1) / 29(2) of the SEBI (SAST) Regulations, 2011 — Acquisition of equity shares of Aptus Pharma Limited (Scrip Code: 544529; ISIN: INE15XJ01010)

Part-A- Details of the Acquisition

Name of the Target Company (TC) Aptus Pharma Limited
Name(s) of the acquirer/Seller and Persons Acting in Concert (PAC) with the acquirer/Seller Mr. Kunjal Piyushbhai Unadkat (Promotor / Promotor Group)
Whether the acquirer/Seller belongs to Promoter/Promotergroup Yes
Name(s) of the Stock Exchange(s) where the shares of TC are Listed BSE Limited (SME)
Details of the acquisition/disposal as follows Number % w.r.t. total share/voting capital wherever applicable (*) % w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition/disposal under consideration, holding of acquirer along with PACs of:
a) Shares carrying voting rights
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/others)
c) Voting rights (VR) otherwise than by equity shares
d) Warrants/convertible securities/any other instrument that entitles the 5,75,000 8.38% 0

acquirer to receive shares carrying voting rights in theTC (specify holding in each category)
e) Total (a+b+c+d) 5,75,000 8.38% 0
Details of acquisition/sale
a) Shares carrying voting rights acquired
b) VRs acquired otherwise than by equityshares
c) Warrants/convertible securities/any otherinstrument that entitles the acquirer to receive shares carrying category) acquired
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/others)
e) Total (a+b+c+d+/-d) 18,000
18,000 0.26%
0.26% 0
0
After the acquisition, Sale, holding of along with PACs of:
a) Shares carrying voting rights
b) VRs otherwise than by equity shares
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in theTC (specify holding in each category) afteracquisition
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/others)
e) Total (a+b+c+d) 5,93,000
5,93,000 8.64%
8.64% 0
0
Mode of acquisition / Sale (e.g. open market / public issue / rights issue / preferential allotment / inter setransfer/encumbrance, etc.) Off-market inter-se transfer among Promoter Group
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc. NA
Date of acquisition of/ Sale of Shares/ date of receipt of intimation of allotment of shares / VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC. 11.05.2026
Equity share capital / total voting capital of the TC before the said acquisition 68,60,000 equity shares of Rs. 10/-
Equity share capital/ total voting capital of the TC after the said acquisition 68,60,000 equity shares of Rs. 10/-

Total diluted share/voting capital of the TC after thesaid acquisition 68,60,000 equity shares of Rs. 10/-

Part-B***

Name of the Target Company: Aptus Pharma Limited (ISIN: INE15XJ01010)

Kunjai P. Unadkat
Kunjal Piyushbhai Unadkat

Place: Rajkot